XML 24 R12.htm IDEA: XBRL DOCUMENT v3.26.1
Accounts payable and accrued liabilities
 3 Months Ended
Mar. 31, 2026
Payables and Accruals [Abstract]  
Accounts payable and accrued liabilities Accounts payable and accrued liabilities
Accounts payable and accrued liabilities were comprised of the following:
 March 31, 2026December 31, 2025
(in thousands)
Trade accounts payable$1,462 $1,173 
Research and development accruals407 412 
Professional fee accruals1,571 1,075 
Payroll accruals789 2,159 
Restructuring liabilities245 640 
Total accounts payable and accrued liabilities$4,474 $5,459 
In March 2025, the Company implemented changes to focus its efforts on advancing the clinical development of imdusiran and AB-101. The decision was made to exit the Company’s corporate headquarters in Warminster, Pennsylvania, implement workforce reductions and discontinue in-house scientific research. The Company recognized $12.9 million of restructuring charges in 2025, of which there was an aggregate of $0.2 million in medical benefit costs and lease expenses accrued as of March 31, 2026.